Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study

In a randomized, evaluator-blind, multicenter trial, we compared cefepime (2 g three times a day) with imipenem-cilastatin (500 mg four times a day) for the treatment of nosocomial pneumonia in 281 intensive care unit patients from 13 centers in six European countries. Of 209 patients eligible for p...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Εκδόθηκε σε:	Antimicrob Agents Chemother
Κύριοι συγγραφείς:	Zanetti, G., Bally, F., Greub, G., Garbino, J., Kinge, T., Lew, D., Romand, J.-A., Bille, J., Aymon, D., Stratchounski, L., Krawczyk, L., Rubinstein, E., Schaller, M.-D., Chiolero, R., Glauser, M.-P., Cometta, A.
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	American Society for Microbiology (ASM) 2003
Θέματα:	Clinical Therapeutics
Διαθέσιμο Online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC253800/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/14576100/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.47.11.3442-3447.2003
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!